Free Trial
NASDAQ:TRDA

Entrada Therapeutics Q3 2023 Earnings Report

Entrada Therapeutics logo
$7.69 +0.19 (+2.48%)
As of 01:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Entrada Therapeutics EPS Results

Actual EPS
$1.02
Consensus EPS
-$0.55
Beat/Miss
Beat by +$1.57
One Year Ago EPS
N/A

Entrada Therapeutics Revenue Results

Actual Revenue
$43.74 million
Expected Revenue
$16.31 million
Beat/Miss
Beat by +$27.43 million
YoY Revenue Growth
N/A

Entrada Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Tuesday, November 7, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Entrada Therapeutics' Q1 2025 earnings is scheduled for Tuesday, August 12, 2025

Entrada Therapeutics Earnings Headlines

HC Wainwright Has Positive Forecast for TRDA Q2 Earnings
Q2 Earnings Forecast for TRDA Issued By HC Wainwright
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
See More Entrada Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Entrada Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entrada Therapeutics and other key companies, straight to your email.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ:TRDA), a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

View Entrada Therapeutics Profile

More Earnings Resources from MarketBeat